In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Democrats Blast HHS For Flu Antiviral Production Shortcomings

This article was originally published in The Pink Sheet Daily

Executive Summary

Democratic members of the House Government Reform Committee question why HHS Secretary Leavitt has not issue a compulsory license to allow other manufacturers to produce Roche's Tamiflu.

You may also be interested in...



Leavitt Defends Bush’s Flu Pandemic Preparedness Plan To Senate

HHS will subsidize about 25% of states’ antiviral costs, leading senators to question whether preparedness in some states could suffer.

Roche Increases Tamiflu Manufacturing Capacity In Time For 2006 Season

President Bush will request $7.1 bil. for pandemic avian flu preparedness, $1 bil. of which will be earmarked for antiviral stockpiling.

“Pharmaco-Metabonomics” Holds Promise for Personalized Drug Therapies, Researchers Say

The method uses a combination of advanced chemical analysis and mathematical modeling to predict drug response.

Topics

UsernamePublicRestriction

Register

PS061342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel